A 65-Year-Old Man with Prostate Cancer

Daniel J. George, MD, presents the case of a 65-year-old man with prostate cancer and offers his initial impressions.

Insights on when to test for BRCA mutations and HRR (homologous recombination repair) status when treating patients with prostate cancer, and whether to utilize tissue testing or ctDNA assays.

An expert oncologist outlines first-line treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC).

A comprehensive overview of the study design and findings from the PROpel trial, which looked at olaparib and abiraterone in patients with metastatic castration-resistant prostate cancer.

Daniel J. George, MD, discusses recent clinical trial data on the PARP inhibitors rucaparib and talazoparib for treatment of prostate cancer.

An expert on prostate cancer provides insights on patients best suited for PARP inhibitor treatment and how to select and sequence therapy.

A medical oncologist discusses situations in which he might recommend abiraterone alongside a PARP inhibitor as first-line treatment for patients with mCRPC.

Daniel J. George, MD, provides insights on how to treat patients with prostate cancer who have pathogenic non-BRCA HRD mutations, and his approach when patients progress on a PARP inhibitor.

Clinical insights on managing adverse events associated with PARP inhibitor therapy in patients with prostate cancer.

Daniel J. George, MD, offers closing thoughts and advice to community oncologists who treat patients with prostate cancer.